Eli Lilly announced plans to invest more than USD 1.2 billion to expand and modernise its Lilly del Caribe manufacturing site in Carolina, Puerto Rico, as part of its broader initiative to enhance pharmaceutical production in the United States.

The expansion will focus on producing oral solid medicines, including the company’s potential weight-loss therapy orforglipron, while also increasing capacity across cardiometabolic, oncology, immunology, and neuroscience portfolios.

The project is expected to create approximately 100 high-tech manufacturing jobs and up to 1,000 construction roles during the build-out phase. Construction is set to begin in 2026, with full-scale production anticipated by late 2028.

This investment is part of Lilly’s larger USD 50 billion USA manufacturing commitment, which includes new and expanded facilities across multiple states, aimed at meeting growing global demand for its innovative medicines.